Sibutramine and the management of obesity.
Sibutramine is a selective serotonin and noradrenaline re-uptake inhibitor approved for the long-term management of obesity. Its primary mechanism of action is increased satiety, although some evidence also suggests increased energy expenditure could play a role in sibutramine-induced weight loss. It has established general efficacy in long-term trials, with clinically-approved doses of 10 and 15 mg. Sibutramine has also been studied in a number of unique populations, including obese controlled hypertensives, diabetics and ethnic minorities, further establishing its effectiveness. However, it does have a consistent effect of increasing blood pressure and pulse. Thus, blood pressure and heart rate should be monitored in patients using sibutramine and it may not be applicable in obese patients with significant cardiovascular disease.
Poston
Walker S Carlos
WS
Mid America Heart Institute and University of Missouri-Kansas City, MO 64110, USA. postonwa@umkc.edu
Foreyt
John P
JP
D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001067:Appetite Depressants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002319:Cardiovascular System / Q000187:drug effects; D002986:Clinical Trials as Topic; D003503:Cyclobutanes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D006801:Humans; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D044469:Racial Groups; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D001067:Appetite Depressants; D003503:Cyclobutanes; D017367:Selective Serotonin Reuptake Inhibitors; C058254:sibutramine